Approximately 99% (183/185) of CML patients are BCR-ABL positive, with the most common type is major b3a2 (136/183; 74.3%), followed by major b2a2 (41/183; 22.4%). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.